MNG1063
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.658
- MYC_TARGETS_V2+0.653
- E2F_TARGETS+0.639
- G2M_CHECKPOINT+0.612
- MTORC1_SIGNALING+0.537
- OXIDATIVE_PHOSPHORYLATION+0.499
- UNFOLDED_PROTEIN_RESPONSE+0.409
- CHOLESTEROL_HOMEOSTASIS+0.353
- DNA_REPAIR+0.352
- PROTEIN_SECRETION+0.345
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.437
- ALLOGRAFT_REJECTION-0.413
- INTERFERON_GAMMA_RESPONSE-0.412
- HEDGEHOG_SIGNALING-0.391
- IL6_JAK_STAT3_SIGNALING-0.390
- INFLAMMATORY_RESPONSE-0.385
- COAGULATION-0.379
- APICAL_SURFACE-0.357
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.355
- COMPLEMENT-0.313
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_G23JJAZY | EPN | Supratentorial EPN | 0.943 |
| 2 | MNG1011 | — | — | 0.941 |
| 3 | MDT-AP-2956 | Med | Medulloblastoma | 0.934 |
| 4 | TCGA-DQ-7588-01A-11R-2081-07 | — | — | 0.932 |
| 5 | BS_G23JJAZY | Supratentorial Ependymoma | — | 0.931 |
| 6 | BS_052PZFMK | high-grade glioma | — | 0.927 |
| 7 | TCGA-BT-A20N-01A-11R-A14Y-07 | — | — | 0.927 |
| 8 | TCGA-AN-A0AK-01A-21R-A00Z-07 | — | C | 0.926 |
| 9 | 1764b9ab-4f37-47c5-8225-40c574433f40 | — | — | 0.924 |
| 10 | BS_MV6ASWV9 | ATRT | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.658 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.653 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.639 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.612 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.537 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.499 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.409 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.353 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.352 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.345 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.313 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.176 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.176 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.175 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.165 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.161 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.148 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.146 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.134 | Idelalisib | — uncovered |
| PEROXISOME | 0.119 | Idelalisib | — uncovered |